Amy B Heimberger

Amy B Heimberger

UNVERIFIED PROFILE

Are you Amy B Heimberger?   Register this Author

Register author
Amy B Heimberger

Amy B Heimberger

Publications by authors named "Amy B Heimberger"

Are you Amy B Heimberger?   Register this Author

100Publications

-Reads

Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.

Cancer Lett 2018 Oct 6;433:176-185. Epub 2018 Jul 6.

Division of Pediatrics and Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address:

View Article
October 2018

Identification of metabolites in plasma for predicting survival in glioblastoma.

Mol Carcinog 2018 Aug 16;57(8):1078-1084. Epub 2018 Apr 16.

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
August 2018

Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma".

Neuro Oncol 2018 Jun;20(7):1003-1004

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
June 2018

Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma.

Mol Carcinog 2018 Jan 10;57(1):137-141. Epub 2017 Oct 10.

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
January 2018

Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.

J Neurooncol 2018 Jan 30;136(1):33-39. Epub 2017 Sep 30.

Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA.

View Article
January 2018

Ependymomas overexpress chemoresistance and DNA repair-related proteins.

Oncotarget 2018 Jan 15;9(8):7822-7831. Epub 2017 Dec 15.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article
January 2018

Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma.

Oncotarget 2017 Nov 5;8(60):101244-101254. Epub 2017 Sep 5.

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA.

View Article
November 2017

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Neuro Oncol 2017 Aug;19(8):1047-1057

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; Caris Life Sciences, Phoenix, Arizona; Departments of Biostatistics, Neuro-Pathology, Neuro-Oncology, Pediatrics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
August 2017

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Cancer Cell 2017 07;32(1):42-56.e6

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic address:

View Article
July 2017

Immune Checkpoint Inhibitors for Brain Metastases.

Curr Oncol Rep 2017 Jun;19(6):38

Royal North Shore Hospital, St Leonards, NSW, Australia.

View Article
June 2017

Immune Checkpoint Inhibitors in Gliomas.

Curr Oncol Rep 2017 Apr;19(4):23

NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW, 1450, Australia.

View Article
April 2017

Tumor Vaccines for Malignant Gliomas.

Neurotherapeutics 2017 04;14(2):345-357

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article
April 2017

Serum microRNA profiling in patients with glioblastoma: a survival analysis.

Mol Cancer 2017 03 11;16(1):59. Epub 2017 Mar 11.

Department of Neuro-Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article
March 2017

Principles of immunotherapy.

Handb Clin Neurol 2016 ;134:163-81

Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article
December 2016

Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?

Immunotherapy 2016 ;8(4):413-23

Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Department of Neurosurgery, 1400 Holcombe Blvd, Unit 442, Houston, TX 77030, USA.

View Article
December 2016

Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells.

Oncotarget 2016 Nov;7(44):72021-72032

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article
November 2016

Interrogating Metabolism in Brain Cancer.

Magn Reson Imaging Clin N Am 2016 Nov;24(4):687-703

Department of Cancer Systems Imaging, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA; The University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address:

View Article
November 2016

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Neuro Oncol 2016 10 1;18(10):1357-66. Epub 2016 Jul 1.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.T.G., Y.H., A.B.H.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.-P.W., J.d.G.); Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (R.G.W.V.); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.Z.); Department of Neuropathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (G.N.F.); Caris Life Sciences, Phoenix, Arizona, USA (J.X., Z.G., S.K.R., D.S.); The University of Sydney, Sydney, Australia (M.K.)

View Article
October 2016

GBM-associated mutations and altered protein expression are more common in young patients.

Oncotarget 2016 Oct;7(43):69466-69478

Departments of Neurosurgery, Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article
October 2016

Immunotherapy in glioblastoma: emerging options in precision medicine.

CNS Oncol 2016 07 26;5(3):175-86. Epub 2016 May 26.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article
July 2016

miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis.

Cancer Res 2016 07 31;76(14):4293-304. Epub 2016 May 31.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

View Article
July 2016

The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Int Rev Immunol 2016 07 26;35(4):325-339. Epub 2014 Sep 26.

a Department of Pediatrics-Research , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article
July 2016

Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.

J Immunother 2016 06;39(5):205-17

*Division of Pediatrics Departments of ‡Biostatistics ∥Neurosurgery §Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center †The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX.

View Article
June 2016

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.

Neuro Oncol 2016 05 11;18(5):639-48. Epub 2015 Dec 11.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas (J.W., E.K.N., L.-Y.K., Y.H., S.X., K.G., X.L., N.H., A.B.H.); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas (W.Q., S.Z.); Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas (C.I.); Departments of Neuropathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (G.N.F.); Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (M.R.G.); Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (W.O.); Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas (G.A.C.); Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China (S.X.).

View Article
May 2016

Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Oncoimmunology 2016 May 21;5(5):e1117739. Epub 2015 Dec 21.

Departments of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.

View Article
May 2016

Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.

Oncotarget 2016 Apr;7(15):20486-95

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article
April 2016

PD-L1 expression and prognostic impact in glioblastoma.

Neuro Oncol 2016 Feb 30;18(2):195-205. Epub 2015 Aug 30.

Departments of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (E.K.N., J.W., N.K.Y., N.H., L.-Y.K., K.G., X.L., A.B.H.); Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (S.Z.); Center for RNA Interference and Non-Coding RNAs, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (C.I.); Flow Cytometry and Cell Imaging Core Facility, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.K.B.); Neuropathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (G.N.F.); Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (G.A.C.); Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (C.A.C.); Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (C.C., K.R.); Lion Biotechnologies, Woodland Hills, California (J.Q.C., L.R.); Dept. of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida (J.Q.C., L.R.).

View Article
February 2016

MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer.

J Gene Ther 2016 Feb 13;2(1). Epub 2016 Feb 13.

Department of Thoracic & Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article
February 2016

Immunosuppressive mechanisms in glioblastoma.

Neuro Oncol 2015 Nov;17 Suppl 7:vii9-vii14

Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (E.K.N., A.B.H.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.).

View Article
November 2015

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Cancer Res 2015 Sep;75(17):3505-18

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas. The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

View Article
September 2015

FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.

J Natl Cancer Inst 2015 Aug 13;107(8). Epub 2015 May 13.

Department of Pediatric Research (JY, JH, DD, XX, SL) and Department of Neurosurgery (LYK, KG, ABH), The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article
August 2015

The role of STAT3 in tumor-mediated immune suppression.

J Neurooncol 2015 Jul 22;123(3):385-94. Epub 2015 Feb 22.

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 1400 Holcombe Blvd., Unit 442, Houston, TX, 77030, USA,

View Article
July 2015

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Neuro Oncol 2015 Jun 13;17(6):854-61. Epub 2015 Jan 13.

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).

View Article
June 2015

FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.

Cancer Res 2015 Jun 1;75(11):2337-48. Epub 2015 Apr 1.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

View Article
June 2015

Therapeutic targets in subependymoma.

J Neuroimmunol 2014 Dec 31;277(1-2):168-75. Epub 2014 Oct 31.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Electronic address:

View Article
December 2014

Immunotherapy for primary brain tumors: no longer a matter of privilege.

Clin Cancer Res 2014 Nov;20(22):5620-9

Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.

View Article
November 2014

Epidermal growth factor receptor and variant III targeted immunotherapy.

Neuro Oncol 2014 Oct;16 Suppl 8:viii20-5

The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).

View Article
October 2014

Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.

Cancer Immunol Res 2014 Sep 17;2(9):867-77. Epub 2014 Jun 17.

Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida.

View Article
September 2014

Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma.

J Natl Cancer Inst 2014 Aug 28;106(8). Epub 2014 Jun 28.

Affiliations of authors: Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China (SX, X-GL), Department of Neurosurgery (SX, JW, FW, L-YK, X-YL, EN, KG, TD, YY, FFL, GR, ABH), Department of Biostatistics (WQ), Department of Pathology (GNF), and Department of Experimental Therapeutics (GAC), University of Texas M. D. Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX (NKY); Texas A&M University College of Veterinary Medicine & Biomedical Sciences, College Station, TX (VF).

View Article
August 2014

MicroRNAs as novel immunotherapeutics.

Oncoimmunology 2013 Aug 28;2(8):e25124. Epub 2013 May 28.

Department of Neurosurgery; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA.

View Article
August 2013

Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.

Cancer Immunol Res 2013 Aug;1(2):112-22

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030.

View Article
August 2013

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Cancer Immunol Immunother 2013 Jun 17;62(6):983-7. Epub 2013 Apr 17.

Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

View Article
June 2013

The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies.

Authors:
Amy B Heimberger

Surg Neurol Int 2011 14;2:163. Epub 2011 Nov 14.

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston TX 77030-4009, USA.

View Article
October 2012

Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.

Oncotarget 2012 Sep;3(9):1036-48

Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article
September 2012

The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.

Int J Cancer 2012 Jul 24;131(1):8-17. Epub 2011 Aug 24.

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article
July 2012

Consensus on the role of human cytomegalovirus in glioblastoma.

Neuro Oncol 2012 Mar 8;14(3):246-55. Epub 2012 Feb 8.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., Unit 442, Houston, TX 77030, USA.

View Article
March 2012

miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.

Clin Investig (Lond) 2011 Dec;1(12):1637-1650

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

View Article
December 2011

Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.

Clin Cancer Res 2011 Jul 13;17(14):4642-9. Epub 2011 Apr 13.

Departments of Neurosurgery and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article
July 2011

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Neuro Oncol 2011 Jan 10;13(1):3-13. Epub 2010 Dec 10.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, FC7.3021, Houston, TX 77030-4009, USA.

View Article
January 2011

Hypoxia potentiates glioma-mediated immunosuppression.

PLoS One 2011 Jan 20;6(1):e16195. Epub 2011 Jan 20.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

View Article
January 2011

Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Clin Cancer Res 2010 Dec 4;16(23):5722-33. Epub 2010 Oct 4.

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article
December 2010

Glioma cancer stem cells induce immunosuppressive macrophages/microglia.

Neuro Oncol 2010 Nov 28;12(11):1113-25. Epub 2010 Jul 28.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article
November 2010

Immune therapeutic targeting of glioma cancer stem cells.

Target Oncol 2010 Sep 25;5(3):217-27. Epub 2010 Aug 25.

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

View Article
September 2010

Clinical applications of a peptide-based vaccine for glioblastoma.

Neurosurg Clin N Am 2010 Jan;21(1):95-109

Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3050, 220 Sands Building, Research Drive, Durham, NC 27710, USA.

View Article
January 2010

The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Neurosurg Clin N Am 2010 Jan;21(1):125-37

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article
January 2010

Glioma-associated cancer-initiating cells induce immunosuppression.

Clin Cancer Res 2010 Jan 12;16(2):461-73. Epub 2010 Jan 12.

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article
January 2010

EGFRvIII-targeted vaccination therapy of malignant glioma.

Brain Pathol 2009 Oct;19(4):713-23

Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article
October 2009

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Expert Opin Biol Ther 2009 Aug;9(8):1087-98

University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Unit 422, Houston, TX 77230-1402, USA.

View Article
August 2009

A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.

Cancer Immunol Immunother 2009 Jul 11;58(7):1023-32. Epub 2008 Nov 11.

Department of Neurosurgery, Unit 442, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

View Article
July 2009

Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.

PLoS One 2009 Jun 17;4(6):e5947. Epub 2009 Jun 17.

Laboratory of Brain Tumor Biology and Genetics, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland.

View Article
June 2009

Topotecan enhances immune clearance of gliomas.

Cancer Immunol Immunother 2009 Feb 2;58(2):259-70. Epub 2008 Jul 2.

Department of Neurosurgery, Unit 442, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article
February 2009

Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers.

Recent Pat CNS Drug Discov 2008 Nov;3(3):179-88

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article
November 2008

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Semin Immunol 2008 Oct 9;20(5):267-75. Epub 2008 Jun 9.

Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

View Article
October 2008

Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.

Clin Cancer Res 2008 Aug;14(16):5166-72

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article
August 2008

Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.

Cancer Immunol Immunother 2008 Jan 24;57(1):123-31. Epub 2007 May 24.

Department of Neurosurgery, Unit 442, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article
January 2008

Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.

Clin Cancer Res 2007 Jun;13(12):3559-67

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article
June 2007

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.

Neuro Oncol 2006 Jul 14;8(3):261-79. Epub 2006 Jun 14.

Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402, USA.

View Article
July 2006